Background/Aims: Carpal tunnel syndrome (CTS) is a common clinical presentation of dialysis-related amyloidosis. It was determined whether β2-microglobulin (β2M) and advanced glycation end products in serum are predictors of CTS in dialysis patients. Methods: A total of 385 hemodialysis patients were screened for CTS. β2M in serum was determined by a competitive enzyme-linked immunoassay, CML by a competitive enzyme-linked immunosorbent assay and total pentosidine by reverse-phase high-performance liquid chromatography. Results: 127 patients (33%) were treated with biocompatible membranes, 174 (45%) with high-flux dialysis. 122 patients (31.7%) had clinical signs of CTS. Significant predictors of CTS were: age, female gender, serum β2M, total protein, dialysis with non-biocompatible high-flux dialysis compared to non-biocompatible low-flux dialysis, Kt/V and serum concentration of CML (OR 2.47 for the 3rd vs. 1st quartile, 95% CI 1.229–4.961, p = 0.011). Conclusion: The prevalence of CTS as a possible manifestation of dialysis-related amyloidosis is still high. Serum concentration of CML may be a predictor of CTS besides β2M and malnutrition.

Keywords:
Advanced glycation end products, β2-Microglobulin, Carpal tunnel syndrome, Dialysis-related amyloidosis, Hemodialysis
1.
Saito A, Gejyo F: Current clinical aspects of dialysis-related amyloidosis in chronic dialysis patients. Ther Apher Dial 2006;10:316–320.
2.
Jadoul M: Dialysis-related amyloidosis: importance of biocompatibility and age. Nephrol Dial Transplant 1998;13(suppl 7): 61–64.
3.
Yamamoto S, Kazama JJ, Narita I, Naiki H, Gejyo F: Recent progress in understanding dialysis-related amyloidosis. Bone 2009;45(suppl 1):S39–S42.
4.
Stein G, Schneider A, Thoss K, Ritz E, Schaefer K, Huller M, Sperschneider H, Marzoll I: Beta 2-microglobulin serum concentration and associated amyloidosis in dialysis patients. Nephrol Dial Transplant 1991;6(suppl 3):57–61.
5.
Miyata T, Taneda S, Kawai R, Ueda Y, Horiuchi S, Hara M, Maeda K, Monnier VM: Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Proc Natl Acad Sci USA 1996;93:2353–2358.
6.
Busch M, Franke S, Ruster C, Wolf G: Advanced glycation end-products and the kidney. Eur J Clin Invest 2010;40:742–755.
7.
Uhlenbusch-Körwer I, Bonnie-Schorn E, Grassmann A, Vienken J (eds): Understanding Membranes and Dialysers. Lengerich, Pabst, 2004, vol 5.
8.
Hoenich NA: Membranes and filters for haemodiafiltration. Contrib Nephrol 2007;158:57–67.
9.
Daugirdas JT: Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 1993;4:1205–1213.
10.
Canaud B, Bosc JY, Leray H, Morena M, Stec F: Microbiologic purity of dialysate: rationale and technical aspects. Blood Purif 2000;18:200–213.
11.
Busch M, Franke S, Muller A, Wolf M, Gerth J, Ott U, Niwa T, Stein G: Potential cardiovascular risk factors in chronic kidney disease: ages, total homocysteine and metabolites, and the C-reactive protein. Kidney Int 2004;66:338–347.
12.
Aroori S, Spence RA: Carpal tunnel syndrome. Ulster Med J 2008;77:6–17.
13.
Yamamoto S, Gejyo F: Historical background and clinical treatment of dialysis-related amyloidosis. Biochim Biophys Acta 2005;1753:4–10.
14.
Otsubo S, Kimata N, Okutsu I, Oshikawa K, Ueda S, Sugimoto H, Mitobe M, Uchida K, Otsubo K, Nitta K, Akiba T: Characteristics of dialysis-related amyloidosis in patients on haemodialysis therapy for more than 30 years. Nephrol Dial Transplant 2009;24:1593–1598.
15.
Schiffl H, Fischer R, Lang SM, Mangel E: Clinical manifestations of ab-amyloidosis: effects of biocompatibility and flux. Nephrol Dial Transplant 2000;15:840–845.
16.
Hakim RM, Wingard RL, Husni L, Parker RA, Parker TF 3rd: The effect of membrane biocompatibility on plasma beta 2-microglobulin levels in chronic hemodialysis patients. J Am Soc Nephrol 1996;7:472–478.
17.
Drueke TB, Massy ZA: Beta2-microglobulin. Semin Dial 2009;22:378–380.
18.
Furuya R, Kumagai H, Takahashi M, Sano K, Hishida A: Ultrapure dialysate reduces plasma levels of beta2-microglobulin and pentosidine in hemodialysis patients. Blood Purif 2005;23:311–316.
19.
Lonnemann G, Koch KM: Beta(2)-microglobulin amyloidosis: effects of ultrapure dialysate and type of dialyzer membrane. J Am Soc Nephrol 2002;13(suppl 1):S72–S77.
20.
Eloot S, Van Biesen W, Dhondt A, Van de Wynkele H, Glorieux G, Verdonck P, Vanholder R: Impact of hemodialysis duration on the removal of uremic retention solutes. Kidney Int 2008;73:765–770.
21.
Himmelfarb J, Stenvinkel P, Ikizler TA, Hakim RM: The elephant in uremia: oxidant stress as a unifying concept of cardiovascular disease in uremia. Kidney Int 2002;62:1524–1538.
22.
Takahashi M, Hoshino H, Kushida K, Murata H, Baba S, Inoue T: The advanced glycation endproduct, pentosidine, in the carpal ligament in patients with carpal tunnel syndrome undergoing hemodialysis: comparison with idiopathic carpal tunnel syndrome. Nephron 1998;80:444–449.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.